Small-Cap Cancer-Focused Nuvation Bio Pulls Plug On Early-Stage Program After Considering Phase 1 Solid Tumor Data
Portfolio Pulse from Vandana Singh
Nuvation Bio Inc. (NYSE:NUVB) has decided to halt the development of its BD2-selective BET inhibitor, NUV-868, after analyzing Phase 1 data. The company will not proceed with Phase 2 studies and is evaluating future steps for the program. NUVB stock fell 7.41% following the announcement.
August 05, 2024 | 6:27 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Nuvation Bio Inc. (NYSE:NUVB) has decided to halt the development of its BD2-selective BET inhibitor, NUV-868, after analyzing Phase 1 data. The company will not proceed with Phase 2 studies and is evaluating future steps for the program. NUVB stock fell 7.41% following the announcement.
The decision to halt the development of NUV-868 is a significant negative development for Nuvation Bio, as it indicates potential issues with the drug's efficacy or safety. This has led to a 7.41% drop in the stock price, reflecting investor concerns.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100
NEUTRAL IMPACT
AstraZeneca Plc (NASDAQ:AZN) was involved in the Phase 1b study of NUV-868 in combination with its drug Lynparza (olaparib). The halt of NUV-868 development may have minor implications for AstraZeneca's collaborative efforts.
AstraZeneca's involvement in the halted NUV-868 study is likely to have a minor impact on the company, as it was only one of many collaborative efforts. The primary focus remains on Nuvation Bio.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 30
NEUTRAL IMPACT
Merck & Co Inc (NYSE:MRK) was involved in the Phase 1b study of NUV-868 in combination with its drug Lynparza (olaparib). The halt of NUV-868 development may have minor implications for Merck's collaborative efforts.
Merck's involvement in the halted NUV-868 study is likely to have a minor impact on the company, as it was only one of many collaborative efforts. The primary focus remains on Nuvation Bio.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 30
NEUTRAL IMPACT
Pfizer Inc (NYSE:PFE) was involved in the Phase 1b study of NUV-868 in combination with its drug Xtandi (enzalutamide). The halt of NUV-868 development may have minor implications for Pfizer's collaborative efforts.
Pfizer's involvement in the halted NUV-868 study is likely to have a minor impact on the company, as it was only one of many collaborative efforts. The primary focus remains on Nuvation Bio.
CONFIDENCE 80
IMPORTANCE 20
RELEVANCE 30